

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on the date shown below:

January 22, 2003

Frank C. Eisenschenk

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT  
Examining Group 1652  
Patent Application  
Docket No. G-045US02PCT  
Serial No. 09/744,527

1652 ✓  
RECEIVED  
JAN 29 2003  
TECH CENTER 1600/2900  
#13/YR  
02-13-03

Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Yong D. Pak  
Art Unit : 1652  
Applicant(s) : Lydie Bougueleret  
Serial No. : 09/744,527  
Filed : January 22, 2001  
Conf. No. : 8473  
For : Nucleic Acid Encoding a Geranyl-Geranyl Pyrophosphatase Synthetase (GGPPS) and Polymorphic Markers Associated with Said

Assistant Commissioner for Patents  
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed below and on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first Office Action on the merits, but before the mailing of a final action or the notice of allowance. Please charge the fee of \$180.00 to Deposit Account No. 19-0065.

01/28/2003 TBESHAH1 00000040 190065 09744527

01 FC:1806 180.00 CH

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO/SB/08 with initials or other appropriate marks. If any additional fee is required, or to credit any overpayment, please use Deposit Account No. 19-0065.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.56, 1.97, and 1.98 are met by the foregoing statements.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: 2421 N.W. 41<sup>st</sup> Street, Suite A-1  
Gainesville, FL 32606-6669

FCE/dkt

Attachments: Form PTO/SB/08 (2 pages)  
Copies of references listed thereon